GlassScriptPhysician profile
Matthew C Caldwell
NPI 1669594859
$876.22
in general payments reported to CMS, 2019-2025
16 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $11.37 · 2021: $23.55 · 2022: $73.75 · 2023: $71.71 · 2024: $376 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $184.46 | 2019-2025 | Argos, Tryptyr |
| Biotissue Holdings INC. | $124.67 | 2021-2025 | |
| Rxsight INC | $109.66 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Tearlab Corp | $63.58 | 2023-2024 | Scoutpro Osmolarity System, Tearlab Osmolarity System |
| Tarsus Pharmaceuticals, INC. | $58.07 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $52.36 | 2023-2025 | Tyrvaya, Ryzumvi |
| Idorsia Pharmaceuticals US INC | $50.12 | 2024 | Quviviq |
| Glaukos Corporation | $47.81 | 2024-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Abbvie INC. | $46.84 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $41.66 | 2023-2024 | Miebo, Xiidra, Alrex |
| Johnson & Johnson Surgical Vision, INC. | $22.58 | 2023 | Veritas Vision System |
| Thea Pharma INC. | $20.10 | 2024 | Iyuzeh |
| Amgen INC. | $20.10 | 2025 | Tepezza |
| Kedrion Biopharma, INC. | $18.03 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Dompe US, INC. | $16.18 | 2025 | Oxervate |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.